A Standardized In Vitro Platform for Senolytic Drug Discovery in Human Musculoskeletal Cells

Authors

Cherif, H., Alsabri, S., Ouellet, J. A., Haglund, L.

Abstract

Cellular senescence contributes to the progression of many age related musculoskeletal diseases. Cellular senescence is a biological state that arises from replicative exhaustion and various cellular stressors, including elevated oxidative stress, mitochondrial dysfunction, mechanical overload, and chronic exposure to pro-inflammatory cytokines and proteases. Although senolytic agents show promise for eliminating senescent cells, their translation has been hindered by the lack of physiologically relevant and scalable in vitro screening methods. In the present study, we developed a standardized, physiologically relevant senescence-induction model and validated a metabolic activity assay as a rapid, scalable method for screening senolytic compounds. We used primary human intervertebral disc cells (IVD) as an example, but the workflow applies to many other cell types. To mimic inflammatory and oxidative stress, we used a combination of TLR-2 activation (Pam2CSK4) and tert-butyl hydroperoxide (tBHP), a potent ROS generator. Senescence induction was validated by quantifying {beta}-galactosidase fluorescence intensity, {beta}-gal enzymatic activity, and the expression of the p16 senescence marker across 3 IVD cell types: nucleus pulposus (NP), inner annulus fibrosus (iAF), and outer annulus fibrosus (oAF) cells. The combined Pam2CSK4 + tBHP exposure generated a robust senescent phenotype across all 3 IVD cell types, with oAF cells exhibiting the strongest increases in {beta}-gal fluorescence, {beta}-gal enzymatic activity, and p16 expression. We then used oAF cells to evaluate if the metabolic activity assay (Alamar Blue) could be used to determine both cytotoxicity of senolytic drugs in non-senescent cells and senolytic activity in a mixed population of senescent and non-senescent cells. We validate the method by comparing metabolic activity results with {beta}-gal enzymatic activity and p16 expression in induced and noninduced cells following exposure to three known senolytics (o-Vanillin, RG-7112, and ABT-199). The metabolic activity assay reliably identified a therapeutic window in which the three senolytics were non-toxic to non-senescent cells while selectively reducing metabolic activity in a mixed population of senescent and non-senescent cells. The reductions in metabolic activity in the mixed population correlated with decreases in SA {beta}-gal enzymatic activity and p16 expression, validating metabolic activity as a sensitive and scalable senolytic readout.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 22 Aug 2026.

Stats

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.